Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary

10/13/2020 | 02:01am EDT

By Joshua Kirby

Nestle SA said Tuesday that it has bought a number of shares in Aimmune Therapeutics Inc., taking its holding in the pharmaceutical company to 84%.

The Swiss food-and-beverage conglomerate said its wholly-owned subsidiary SPN MergerSub had purchased around 43.4 million shares via a tender offer at a price of $34.50 per share. Added to the shares already owned by Nestle and its subsidiaries, it represents around 84% of the outstanding shares in Aimmune Therapeutics, the company said.

SPN MergerSub will be merged with Aimmune Therapeutics, which will continue as the surviving corporation, Nestle said.

Write to Joshua Kirby at joshua.kirby@dowjones.com

(END) Dow Jones Newswires

10-13-20 0200ET

Stocks mentioned in the article
ChangeLast1st jan.
NESTLÉ S.A. 0.29% 116 Delayed Quote.10.93%
All news about AIMMUNE THERAPEUTICS, INC.
02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
DJ
01/22AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
01/05AIMMUNE THERAPEUTICS  : European Commission approves first treatment for peanut ..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission Approves Aimmune's PALFORZIA® as Fir..
BU
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement, Co..
AQ
2020AIMMUNE THERAPEUTICS  : Receives Positive CHMP Opinion on PALFORZIA for the Trea..
AQ
2020MONTEVERDE & ASSOCIATES PC  : Files Class Action Lawsuit On Behalf Of Shareholde..
PR
2020AIMMUNE THERAPEUTICS  : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
Stacey Denenberg Seltzer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.0.00%2 268
GILEAD SCIENCES, INC.14.40%83 591
WUXI APPTEC CO., LTD.36.51%69 433
BIONTECH SE181.53%55 429
REGENERON PHARMACEUTICALS9.66%54 864
VERTEX PHARMACEUTICALS-20.66%48 542